CN107158205A - A kind of pharmaceutical composition for treating hypertension - Google Patents
A kind of pharmaceutical composition for treating hypertension Download PDFInfo
- Publication number
- CN107158205A CN107158205A CN201710446470.4A CN201710446470A CN107158205A CN 107158205 A CN107158205 A CN 107158205A CN 201710446470 A CN201710446470 A CN 201710446470A CN 107158205 A CN107158205 A CN 107158205A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- hypertension
- extract
- raw material
- soybean lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The present invention relates to traditional Chinese medicine and drug field, more particularly to a kind of pharmaceutical composition for treating hypertension.Pharmaceutical composition of the present invention is made up of grape seed extract, Celeryseed extract, garlic powder, soybean lecithin, preferred tablet, capsule and granule.Pharmacological testing confirms that pharmaceutical composition of the present invention has preferable therapeutic action to high blood pressure, and pharmaceutical composition prescription of the present invention it is simple, widely applicable, using safety and treatment cost is very low.
Description
Technical field
The present invention relates to traditional Chinese medicine and drug field, more particularly to a kind of pharmaceutical composition for treating hypertension.
Background technology
Hypertension (hypertension) refers to increase to be main with systemic arterial blood pressure (systolic pressure and/or diastolic pressure)
Feature (millimetres of mercury of systolic pressure >=140, the millimetres of mercury of diastolic pressure >=90), can with the organs such as the heart, brain, kidney function or device matter
Property infringement clinical syndrome.Hypertension is most common chronic disease, is also the topmost hazards of cardiovascular and cerebrovascular diseases.
High blood pressure belongs to the traditional Chinese medical science " dizziness " and " headache " category, and the traditional Chinese medical science thinks this of its disease for imbalance of yin and yang, the mark of its disease
For interior raw wind, phlegm, hemostasis.Liver-yang hyperactivity, hyperactivity of yang due to yin deficiency, the deficiency of liver-yin and kidney-yin and yin-yang deficiency four are classified as on tcm clinical practice
Card type and interior wind, blood stasis, phlegm hinder three accompanying symptoms.
Treating the medicine of hypertension mainly includes renin angiotensin converting enzyme inhibitor, calcium ion antagonist, diuresis
The Western medicine such as agent, vasodilator, sympathetic inhibitor and many Chinese prescriptions.But said medicine therapy still have some shortcomings it
Place, for example, Western medicine is generally symptomatic treatment, takes stopgap measures without effecting a permanent cure, and the state of an illness easily recurs, adverse reaction is more, be also easy to produce drug resistance, length
Phase, which uses, can also produce dependence and withdrawal reaction；Though oral traditional Chinese medicine fundamentally can carry out comprehensively regulating to disease, often
The relatively slow and curative effect that works is simultaneously imprecise, and Chinese medicine is taken in addition needs diagnosis and treatment based on an overall analysis of the illness and the patient's condition, arbitrarily takes and is likely to that effect is not good or even meeting
The state of an illness is aggravated, the defect of these drug therapies largely reduces the tolerance and compliance of patient.
At present, some natural drug compositions also are used for assisting in treating hypertension and achieve certain curative effect, for example,
Disclose a kind of suitable for hypertension patent application CN201610582362.5 " suitable for the health food of hyperpietic "
The health food of patient, by chitin, lecithin, fish oil, spirulina, B B-complex, propolis, grape pip, galic essential oil and
Pearl powder is made.One kind, which is disclosed, in patent of invention CN201210548918.0 " a kind of Chinese patent drug for hypertension " treats height
The Chinese patent drug of blood pressure, is by Dracocephalum moldavica, lemon balm, lavender, rose, oral shui solution, folium sennae, wolf's milk, the fruit of Chinese wolfberry, witloof
Son, celery seed, fennel seeds, wrinkled giant hyssop and medicine jujube are made.But, similar pharmaceutical composition often constitutes complexity, and production technology is difficult
Degree is big, and very big difficulty can be caused to the quality control of product, is unfavorable for keeping the stability of product quality.
The content of the invention
The invention provides a kind of pharmaceutical composition for treating hypertension, pharmaceutical composition composition of the present invention is simple, curative effect
Definitely, it is widely applicable and treatment cost is relatively low.
The pharmaceutical composition all the components of present invention treatment hypertension are natural conventional food extract, and it uses peace
Full property is very high.
The pharmaceutical composition of present invention treatment hypertension, it is characterised in that it is made up of the raw material of following weight parts：
Grape seed extract 300-325, Celeryseed extract 280-300, garlic powder 560-600, soybean lecithin 580-
600；
The grape seed extract is made by the following method：Grape pip is dried, crush after add 8-10 times measure 30%
Filter residue is repeated into filtering after extracting 1 time, merging under ethanol, refluxing extraction 1 hour after soaking 2 hours, decoction filtration, the same terms
Filtrate, is concentrated under reduced pressure into after small size and is spray-dried, obtain grape seed extract；
The Celeryseed extract is made by the following method：Celery seed is dried, crush after add 8-10 times measure water, soak
Bubble is decocted 1 hour after 1 hour, decoction filtration, discards filtrate, and 10 times of amount petroleum ethers of addition into filter residue：Ethyl acetate=1：3
Mixed solvent, refluxing extraction 1 hour, filtering, filtrate decompression is concentrated into after small size and is dried in vacuo, and obtains Celeryseed extract.
The parts by weight of above-mentioned raw materials are preferred：
Grape seed extract 300, Celeryseed extract 280, garlic powder 560, soybean lecithin 580.
The parts by weight of above-mentioned raw materials are further preferably：
Grape seed extract 310, Celeryseed extract 290, garlic powder 580, soybean lecithin 590.
The parts by weight of above-mentioned raw materials are further preferably：
Grape seed extract 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600.
Further, the raw material of described pharmaceutical composition, which is made, also includes following weight parts：Dento liva 150-165.
Preferably, the dento liva is Ultramicro-powder, and fineness is 300-500 mesh.
As a preferred embodiment, pharmaceutical composition of the present invention is made up of the raw material of following weight parts：
Grape seed extract 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600, dento liva Ultramicro-powder
160。
Further, by described pharmaceutical composition by the conventional method for preparing tablet, capsule or granule in this area,
This medicinal composition tablets, capsule or granule is made.
Moreover, it relates to a kind of pharmaceutical composition for treating hypertension answering in treatment hypertension drug is prepared
With.
Through experiment, pharmaceutical composition of the present invention has preferable therapeutic action to high blood pressure, and the present invention it is widely applicable,
Treatment cost is very low；In addition, all raw materials of the invention are natural food extract, use is very safe and reliable, it is adaptable to each
Type hyperpietic, therefore, pharmaceutical composition of the present invention are especially suitable for current clinical demand, and popularization and application of the invention will
There can be good market prospects and produce considerable economy and social benefit.
Embodiment
Illustrate embodiments of the present invention below by way of specific instantiation, those skilled in the art can be by this specification
Disclosed content understands other advantages and effect of the present invention easily.The present invention can also pass through specific realities different in addition
The mode of applying is embodied or practiced, the various details in this specification can also based on different viewpoints with application, without departing from
Various modifications or alterations are carried out under the spirit of the present invention.
Before the specific embodiment of the invention is further described, it should be appreciated that protection scope of the present invention is not limited to down
State specific specific embodiment；It is also understood that the term used in the embodiment of the present invention is specific specific in order to describe
Embodiment, the protection domain being not intended to be limiting of the invention.
When embodiment provides number range, it should be appreciated that except non-invention is otherwise noted, two ends of each number range
Any one numerical value can select between point and two end points.Unless otherwise defined, in the present invention all technologies for using and
Scientific terminology is identical with the meaning that those skilled in the art of the present technique are generally understood that.Except the specific method used in embodiment, equipment,
Outside material, according to those skilled in the art to the grasp of prior art and the record of the present invention, it can also use and this
Any method, equipment and the material of the similar or equivalent prior art of method, equipment described in inventive embodiments, material come real
The existing present invention.
The therapeutic effect of pharmaceutical composition of the present invention is described in detail below in conjunction with specific embodiment and comparative example.
Embodiment 1
A kind of pharmaceutical composition for treating hypertension, this pharmaceutical composition is made up of the raw material of following weight parts：
Grape seed extract 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600, dento liva Ultramicro-powder
160。
Embodiment 2
A kind of pharmaceutical composition for treating hypertension, this pharmaceutical composition is made up of the raw material of following weight parts：
Grape seed extract 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600.
Embodiment 3
A kind of pharmaceutical composition for treating hypertension, this pharmaceutical composition is made up of the raw material of following weight parts：
Grape seed extract 300, Celeryseed extract 280, garlic powder 560, soybean lecithin 580.
Embodiment 4
A kind of pharmaceutical composition for treating hypertension, this pharmaceutical composition is made up of the raw material of following weight parts：
Grape seed extract 310, Celeryseed extract 290, garlic powder 580, soybean lecithin 590.
Comparative example
A kind of pharmaceutical composition for treating hypertension, this pharmaceutical composition is made up of the raw material of following weight parts：
Grape seed extract 325, garlic powder 600, soybean lecithin 600.
Pharmacodynamic experiment
Pharmacodynamics test is carried out to obtained pharmaceutical composition in above-described embodiment and comparative example.
1. experiment purpose
Influence of the observation pharmaceutical composition of the present invention to hypertension mouse blood pressure level.
2. experiment material
2.1 medicine
2.1.1 test medicine
Pharmaceutical composition made from embodiment 1-4, comparative example.
Compound method：It is configured to suspension of the concentration as 30.0mg/ml respectively using water.
2.1.2 positive drug
Captopril tablets.
Compound method：Grind into powder is configured to suspension of the concentration as 2.50mg/ml using water.
2.1.3 modeling agent
L-NAME (L-NAME).
2.2 experimental animal
Wistar rats, 3-4 week old.
3. experimental method
3.1 modeling method
100 rats are randomly selected, 10 are only used as blank control, and 90 are modeling group, modeling group rat N- nitros-L-
Arginine methyl esters 15mg/ (kg ﹒ d) is injected intraperitoneally in two times, continuous 4 weeks.
Compared with blank control rat, the 1st week blood pressure starts rise after modeling group rat modeling, is in gradually to increase later
Gesture, was continuous stability hypertension to the 2nd week, points out modeling success.
3.2 medication
Experiment packet：Selective body heavy phase is near from modeling successful rat 70, are randomly divided into 7 groups, i.e. blank control
Group (not medication), positive drug group (captopril), test medicine group (embodiment 1-4), control drug group (comparative example).
Method of administration：Oral administration gavage is administered.
Administering mode and dosage
Test medicine group and control drug group：300mg/kg body weight, is administered by 0.1ml/10g body weight, daily to weigh sooner or later
After body weight, test medicine or control drug suspension are given respectively；
Positive drug group：12.5mg/kg body weight, is administered by 0.1ml/10g body weight, after weighing in sooner or later daily, given
Captopril suspension.
Successive administration 15 days.
4. experimental result
Living animal observation index
General clinical observation：Including but not limited to death condition, the state of mind, behavioral activity, morbidity, breathing, secretion,
Excrement and diet and drinking-water situation etc..
Detailed clinical is observed：The including but not limited to state of mind, behavioral activity, skin, hair, eyes, ear, nose, abdomen
Portion, external genital organs, anus, four limbs, foot and breathing.
Body weight：All animals determine body weight with before being grouped after the receipt, and determine body weight before the dying euthanasia of animal.
Observation index：Pressure value before and after administration.
Assay method：The indirect blood pressure (systolic pressure) of rat under waking state is determined using tail volumetric method.
Determine the record time：Before first administration and D16.
Pressure value result is as shown in table 1 below before and after the administration of each group animal：
Pressure value before and after the administration of each group animal of table 1
| Packet | n | Blood pressure (mmHg) before administration | Blood pressure (mmHg) after administration |
| Blank control group | 10 | 129.6±14.1 | 134.7±15.3 |
| Positive drug group | 10 | 127.3±13.9 | 102.6±23.2** |
| 1 group of embodiment | 10 | 131.8±17.2 | 87.7±16.0*** |
| 2 groups of embodiment | 10 | 125.7±13.7 | 96.9±14.6** |
| 3 groups of embodiment | 10 | 125.2±19.0 | 98.1±20.3** |
| 4 groups of embodiment | 10 | 130.7±17.6 | 100.3±13.7** |
| Comparative example group | 10 | 129.6±10.3 | 111.5±12.4* |
Note：Compared with blank control group：*P≤0.05；**P≤0.01；***P≤0.001.
From table 1 it follows that compared with blank control group, during off-test, each group rat blood pressure value has different journeys
The reduction of degree, points out the hypertension degree of each group rat to mitigate.Comparatively, pharmaceutical composition (embodiment of the present invention
Antihypertensive effect 1-4), which is better than in positive drug captopril, comparative example drug regimen composition formula, is free of Celeryseed extract,
Therefore its antihypertensive effect is substantially poor, so as to illustrate in the prescription of this pharmaceutical composition, Celeryseed extract and other raw materials
Between can produce certain cooperative effect, fundamental role is served in pressure reduction jointly.It is further preferred that
Dento liva Ultramicro-powder is contained in the prescription of embodiment 1, its antihypertensive effect is protruded the most, has pointed out addition dento liva ultra micro meal component
With the effect for further improving this pharmaceutical composition antihypertensive effect.
The preferred embodiments of the disclosure and embodiment are explained in detail above, but the present invention is not limited to
The above-described embodiment and examples, in the knowledge that those skilled in the art possess, can also not depart from the present invention
Various changes can be made on the premise of design.
Claims (9)
1. a kind of pharmaceutical composition for treating hypertension, it is characterised in that it is made up of the raw material of following weight parts：Grape
Seed extract 300-325, Celeryseed extract 280-300, garlic powder 560-600, soybean lecithin 580-600；
The grape seed extract is made by the following method：Grape pip is dried, crush after add 8-10 times measure 30% ethanol,
Filtered after filter residue repetition is extracted 1 time under refluxing extraction 1 hour after soaking 2 hours, decoction filtration, the same terms, merging filtrate,
It is concentrated under reduced pressure into after small size and is spray-dried, obtains grape seed extract；
The Celeryseed extract is made by the following method：Celery seed is dried, crush after add 8-10 times and measure water, immersion 1
Decocted 1 hour after hour, decoction filtration discards filtrate, and 10 times are added into filter residue and measure petroleum ethers：Ethyl acetate=1：3 mix
Bonding solvent, refluxing extraction 1 hour, filtering, filtrate decompression is concentrated into after small size and is dried in vacuo, and obtains Celeryseed extract.
2. the pharmaceutical composition of hypertension is treated as claimed in claim 1, wherein the parts by weight of each raw material are：Grape pip is extracted
Thing 300, Celeryseed extract 280, garlic powder 560, soybean lecithin 580.
3. the pharmaceutical composition of hypertension is treated as claimed in claim 1, wherein the parts by weight of each raw material are：Grape pip is extracted
Thing 310, Celeryseed extract 290, garlic powder 580, soybean lecithin 590.
4. the pharmaceutical composition of hypertension is treated as claimed in claim 1, wherein the parts by weight of each raw material are：Grape pip is extracted
Thing 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600.
5. treating the pharmaceutical composition of hypertension as claimed in claim 1, the raw material of described pharmaceutical composition, which is made, also to be included
Following weight parts：Dento liva 150-165.
6. treating the pharmaceutical composition of hypertension as claimed in claim 5, the dento liva is Ultramicro-powder, and fineness is 300-
500 mesh.
7. the pharmaceutical composition of hypertension is treated as claimed in claim 6, wherein the parts by weight of each raw material are：Grape pip is extracted
Thing 325, Celeryseed extract 300, garlic powder 600, soybean lecithin 600, dento liva Ultramicro-powder 160.
8. the pharmaceutical composition of the treatment hypertension as described in claim any one of 1-7, it is characterised in that the drug regimen
This medicinal composition tablets, capsule is further made by the conventional method for preparing tablet, capsule or granule in this area in thing
Agent or granule.
9. the pharmaceutical composition of the treatment hypertension as described in claim any one of 1-7 is in treatment hypertension drug is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710446470.4A CN107158205B (en) | 2017-06-14 | 2017-06-14 | A pharmaceutical composition for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710446470.4A CN107158205B (en) | 2017-06-14 | 2017-06-14 | A pharmaceutical composition for treating hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107158205A true CN107158205A (en) | 2017-09-15 |
| CN107158205B CN107158205B (en) | 2020-06-23 |
Family
ID=59818547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710446470.4A Expired - Fee Related CN107158205B (en) | 2017-06-14 | 2017-06-14 | A pharmaceutical composition for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107158205B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007015A (en) * | 2007-01-17 | 2007-08-01 | 北京天川军威医药技术开发有限公司 | Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout |
| CN105975764A (en) * | 2016-04-29 | 2016-09-28 | 广州中元泰健康管理有限公司 | Health management system and method |
| WO2016187258A1 (en) * | 2015-05-19 | 2016-11-24 | Vascure Natural, Inc. | Synergistic natural cardiovascular support supplement and method |
-
2017
- 2017-06-14 CN CN201710446470.4A patent/CN107158205B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007015A (en) * | 2007-01-17 | 2007-08-01 | 北京天川军威医药技术开发有限公司 | Application of flavonoids of celery seed and coumarins in preparation of drug for preventing and treating gout |
| WO2016187258A1 (en) * | 2015-05-19 | 2016-11-24 | Vascure Natural, Inc. | Synergistic natural cardiovascular support supplement and method |
| CN105975764A (en) * | 2016-04-29 | 2016-09-28 | 广州中元泰健康管理有限公司 | Health management system and method |
Non-Patent Citations (7)
| Title |
|---|
| 加百列: "《如何选择营养素》", 30 June 2009, 中国社会出版社 * |
| 吴凌: "《高血压这样吃更健康》", 31 August 2014, 安徽科学技术出版社 * |
| 国家标准频道: "研究称大蒜可治疗高血压", 《食品与发酵工业》 * |
| 杨炳坤等: "芹菜籽治疗高血压病25例", 《广西中医药》 * |
| 清莲漂香: "生芹菜伴大蒜治高血压效果很好", 《HTTP://BLOG.SINA.COM.CN/S/BLOG_B54C7F4F0102WNNT.HTML》 * |
| 童汉清等: "橄榄核油的超临界CO2萃取及GC-MS分析", 《食品工业》 * |
| 籽谷养生: "芹菜籽+葡萄籽强效降压秘方", 《HTTP://BLOG.SINA.COM.CN/S/BLOG_87F0743A0100V4E9.HTML》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107158205B (en) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102886033B (en) | Traditional Chinese medicine preparation for promoting postpartum recovery of parturients and shortening lochial time | |
| CN100528214C (en) | Capsule for treating epilepsia and its preparing method | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN107744571B (en) | Pharmaceutical composition for improving vascular endothelial dysfunction and preparation method and application thereof | |
| CN102846793A (en) | Composition for stagnant blood constitution, and preparation method and application of composition | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN104983987A (en) | Traditional Chinese medicine colon dialyzate treating chronic renal failure | |
| CN102178759B (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method of composition | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN107158205A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN106421727A (en) | Traditional Chinese medicine composition for treating painful menstruation and preparation method and application thereof | |
| CN102641357A (en) | Medicament for treating hypertension and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN106309727B (en) | A kind of Chinese medicine composition for preventing and treating kidney deficiency blood stasis type diabetes B cognition dysfunction | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN104189314B (en) | It is a kind of to treat the turbid pharmaceutical composition for checking card high fat of blood of phlegm | |
| US8486460B2 (en) | Herbal composition for lowering likelihood of stroke and methods for healing stroke patients | |
| CN105395650A (en) | Applications of Shu Gan Ning preparation in preparation of medicines treating osteoporosis and complications of the osteoporosis | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN106728819A (en) | A kind of medicine and preparation method for treating chronic dermatitis | |
| CN105169090B (en) | A kind of gastrodia tuber eucommia compound medicament composition | |
| CN106361984A (en) | Nine-raw-material blood stanching powder and preparing method and application thereof | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN107335026B (en) | Medicine for treating focal segmental glomerulosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Changrun Inventor after: Wei Yiyu Inventor before: Li Changrun |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200623 Termination date: 20210614 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |